Company Introduction

GenePharma (NEEQ: 430601) is a biotech company focusing on RNA-based technologies, -services and -supplies. GenePharma has established a comprehensive RNA manufacturing facility to provide a wide range of open-access technology platforms and services for RNAi, gRNA, mRNA therapeutics and RNA biomarkers. Using our RNAi technology, GenePharma supports contract researchers in their aim to unravel gene function in healthy and disease systems, and to develop therapeutics using CRISPR-based genome editing or RNA-based drugs.

Patent Breakthroughs: Forging a Solid Foundation for Innovation with Core Technology

In 2025, GenePharma continued to deepen its R&D efforts in the core technology field of nucleic acid drugs, filing 30 new invention patents covering key areas such as small nucleic acid drug modification methods, among which 3 patents were granted. To date, the company has accumulated a total of 152 invention patent applications and secured 71 authorizations, further consolidating its leading position in the siRNA (small nucleic acid) technology sector.

We have collaborated with pharmaceutical partners to co-develop more than 10 small nucleic acid drug candidates. Among these achievements, the first small nucleic acid drug IND application filed by our partner has been accepted, and the first dual-target small nucleic acid drug has been selected for oral presentations at international conferences twice—fully demonstrating its FIC (First-in-Class) and BIC (Best-in-Class) potential.

Scientific Research Endorsement: Globally Recognized Academic Influence

In 2025, our technologies and products were cited in over 6,400 SCI papers, among which 870 were high-quality publications with an Impact Factor (IF) greater than 10. By the end of 2025, we had accumulated more than 80,000 SCI paper citations with a total Impact Factor exceeding 350,000. Meanwhile, we have established in-depth collaborations with over 70,000 partners worldwide, covering universities, research institutes, medical institutions and other fields, emerging as a reliable core partner in nucleic acid-related innovative research.